The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Pharmacogenomics (PGx)-Global Market Insights and Sales Trends 2025
Synopsis
The global Pharmacogenomics (PGx) market size is expected to reach US$ 14590 million by 2029, growing at a CAGR of 9.3% from 2023 to 2029. The market is mainly driven by the significant applications of Pharmacogenomics (PGx) in various end use industries. The expanding demands from the Cardiovascular Diseases (CVD), Central Nervous System (CNS), Cancer/Oncology and Infectious Diseases, are propelling Pharmacogenomics (PGx) market. Polymerase Chain Reaction (PCR), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Microarray segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Pharmacogenomics (PGx), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Pharmacogenomics (PGx) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Pharmacogenomics (PGx) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Pharmacogenomics (PGx) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Pharmacogenomics (PGx) covered in this report include Abbott Laboratories, Affymetrix, Inc., Assurex Health, Inc, Astrazeneca, GeneDX, Illumina, Inc., Laboratory Corporation of America Holdings, Myriad Genetics, Inc. and Pathway Genomics, etc.
The global Pharmacogenomics (PGx) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott Laboratories
Affymetrix, Inc.
Assurex Health, Inc
Astrazeneca
GeneDX
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics, Inc.
Pathway Genomics
Pfizer, Inc
Qiagen, Inc.
Rocheg
Teva Pharmaceutical Industries Ltd.
Thermo Fisher Scientific
Transgenomic, Inc.
Global Pharmacogenomics (PGx) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Pharmacogenomics (PGx) market, Segment by Type:
Polymerase Chain Reaction (PCR)
Microarray
Sequencing
Other
Global Pharmacogenomics (PGx) market, by Application
Cardiovascular Diseases (CVD)
Central Nervous System (CNS)
Cancer/Oncology
Infectious Diseases
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Pharmacogenomics (PGx) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Pharmacogenomics (PGx) market size is expected to reach US$ 14590 million by 2029, growing at a CAGR of 9.3% from 2023 to 2029. The market is mainly driven by the significant applications of Pharmacogenomics (PGx) in various end use industries. The expanding demands from the Cardiovascular Diseases (CVD), Central Nervous System (CNS), Cancer/Oncology and Infectious Diseases, are propelling Pharmacogenomics (PGx) market. Polymerase Chain Reaction (PCR), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Microarray segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Pharmacogenomics (PGx), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Pharmacogenomics (PGx) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Pharmacogenomics (PGx) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Pharmacogenomics (PGx) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Pharmacogenomics (PGx) covered in this report include Abbott Laboratories, Affymetrix, Inc., Assurex Health, Inc, Astrazeneca, GeneDX, Illumina, Inc., Laboratory Corporation of America Holdings, Myriad Genetics, Inc. and Pathway Genomics, etc.
The global Pharmacogenomics (PGx) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott Laboratories
Affymetrix, Inc.
Assurex Health, Inc
Astrazeneca
GeneDX
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics, Inc.
Pathway Genomics
Pfizer, Inc
Qiagen, Inc.
Rocheg
Teva Pharmaceutical Industries Ltd.
Thermo Fisher Scientific
Transgenomic, Inc.
Global Pharmacogenomics (PGx) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Pharmacogenomics (PGx) market, Segment by Type:
Polymerase Chain Reaction (PCR)
Microarray
Sequencing
Other
Global Pharmacogenomics (PGx) market, by Application
Cardiovascular Diseases (CVD)
Central Nervous System (CNS)
Cancer/Oncology
Infectious Diseases
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Pharmacogenomics (PGx) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Pharmacogenomics (PGx)
1.1 Pharmacogenomics (PGx) Market Overview
1.1.1 Pharmacogenomics (PGx) Product Scope
1.1.2 Pharmacogenomics (PGx) Market Status and Outlook
1.2 Global Pharmacogenomics (PGx) Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Pharmacogenomics (PGx) Market Size by Region (2018-2029)
1.4 Global Pharmacogenomics (PGx) Historic Market Size by Region (2018-2023)
1.5 Global Pharmacogenomics (PGx) Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Pharmacogenomics (PGx) Market Size (2018-2029)
1.6.1 North America Pharmacogenomics (PGx) Market Size (2018-2029)
1.6.2 Europe Pharmacogenomics (PGx) Market Size (2018-2029)
1.6.3 Asia-Pacific Pharmacogenomics (PGx) Market Size (2018-2029)
1.6.4 Latin America Pharmacogenomics (PGx) Market Size (2018-2029)
1.6.5 Middle East & Africa Pharmacogenomics (PGx) Market Size (2018-2029)
2 Pharmacogenomics (PGx) Market by Type
2.1 Introduction
2.1.1 Polymerase Chain Reaction (PCR)
2.1.2 Microarray
2.1.3 Sequencing
2.1.4 Other
2.2 Global Pharmacogenomics (PGx) Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Pharmacogenomics (PGx) Historic Market Size by Type (2018-2023)
2.2.2 Global Pharmacogenomics (PGx) Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Pharmacogenomics (PGx) Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Pharmacogenomics (PGx) Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Pharmacogenomics (PGx) Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Pharmacogenomics (PGx) Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Pharmacogenomics (PGx) Revenue Breakdown by Type (2018-2029)
3 Pharmacogenomics (PGx) Market Overview by Application
3.1 Introduction
3.1.1 Cardiovascular Diseases (CVD)
3.1.2 Central Nervous System (CNS)
3.1.3 Cancer/Oncology
3.1.4 Infectious Diseases
3.1.5 Other
3.2 Global Pharmacogenomics (PGx) Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Pharmacogenomics (PGx) Historic Market Size by Application (2018-2023)
3.2.2 Global Pharmacogenomics (PGx) Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Pharmacogenomics (PGx) Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Pharmacogenomics (PGx) Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Pharmacogenomics (PGx) Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Pharmacogenomics (PGx) Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Pharmacogenomics (PGx) Revenue Breakdown by Application (2018-2029)
4 Pharmacogenomics (PGx) Competition Analysis by Players
4.1 Global Pharmacogenomics (PGx) Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Pharmacogenomics (PGx) as of 2022)
4.3 Date of Key Players Enter into Pharmacogenomics (PGx) Market
4.4 Global Top Players Pharmacogenomics (PGx) Headquarters and Area Served
4.5 Key Players Pharmacogenomics (PGx) Product Solution and Service
4.6 Competitive Status
4.6.1 Pharmacogenomics (PGx) Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Abbott Laboratories
5.1.1 Abbott Laboratories Profile
5.1.2 Abbott Laboratories Main Business
5.1.3 Abbott Laboratories Pharmacogenomics (PGx) Products, Services and Solutions
5.1.4 Abbott Laboratories Pharmacogenomics (PGx) Revenue (US$ Million) & (2018-2023)
5.1.5 Abbott Laboratories Recent Developments
5.2 Affymetrix, Inc.
5.2.1 Affymetrix, Inc. Profile
5.2.2 Affymetrix, Inc. Main Business
5.2.3 Affymetrix, Inc. Pharmacogenomics (PGx) Products, Services and Solutions
5.2.4 Affymetrix, Inc. Pharmacogenomics (PGx) Revenue (US$ Million) & (2018-2023)
5.2.5 Affymetrix, Inc. Recent Developments
5.3 Assurex Health, Inc
5.3.1 Assurex Health, Inc Profile
5.3.2 Assurex Health, Inc Main Business
5.3.3 Assurex Health, Inc Pharmacogenomics (PGx) Products, Services and Solutions
5.3.4 Assurex Health, Inc Pharmacogenomics (PGx) Revenue (US$ Million) & (2018-2023)
5.3.5 Astrazeneca Recent Developments
5.4 Astrazeneca
5.4.1 Astrazeneca Profile
5.4.2 Astrazeneca Main Business
5.4.3 Astrazeneca Pharmacogenomics (PGx) Products, Services and Solutions
5.4.4 Astrazeneca Pharmacogenomics (PGx) Revenue (US$ Million) & (2018-2023)
5.4.5 Astrazeneca Recent Developments
5.5 GeneDX
5.5.1 GeneDX Profile
5.5.2 GeneDX Main Business
5.5.3 GeneDX Pharmacogenomics (PGx) Products, Services and Solutions
5.5.4 GeneDX Pharmacogenomics (PGx) Revenue (US$ Million) & (2018-2023)
5.5.5 GeneDX Recent Developments
5.6 Illumina, Inc.
5.6.1 Illumina, Inc. Profile
5.6.2 Illumina, Inc. Main Business
5.6.3 Illumina, Inc. Pharmacogenomics (PGx) Products, Services and Solutions
5.6.4 Illumina, Inc. Pharmacogenomics (PGx) Revenue (US$ Million) & (2018-2023)
5.6.5 Illumina, Inc. Recent Developments
5.7 Laboratory Corporation of America Holdings
5.7.1 Laboratory Corporation of America Holdings Profile
5.7.2 Laboratory Corporation of America Holdings Main Business
5.7.3 Laboratory Corporation of America Holdings Pharmacogenomics (PGx) Products, Services and Solutions
5.7.4 Laboratory Corporation of America Holdings Pharmacogenomics (PGx) Revenue (US$ Million) & (2018-2023)
5.7.5 Laboratory Corporation of America Holdings Recent Developments
5.8 Myriad Genetics, Inc.
5.8.1 Myriad Genetics, Inc. Profile
5.8.2 Myriad Genetics, Inc. Main Business
5.8.3 Myriad Genetics, Inc. Pharmacogenomics (PGx) Products, Services and Solutions
5.8.4 Myriad Genetics, Inc. Pharmacogenomics (PGx) Revenue (US$ Million) & (2018-2023)
5.8.5 Myriad Genetics, Inc. Recent Developments
5.9 Pathway Genomics
5.9.1 Pathway Genomics Profile
5.9.2 Pathway Genomics Main Business
5.9.3 Pathway Genomics Pharmacogenomics (PGx) Products, Services and Solutions
5.9.4 Pathway Genomics Pharmacogenomics (PGx) Revenue (US$ Million) & (2018-2023)
5.9.5 Pathway Genomics Recent Developments
5.10 Pfizer, Inc
5.10.1 Pfizer, Inc Profile
5.10.2 Pfizer, Inc Main Business
5.10.3 Pfizer, Inc Pharmacogenomics (PGx) Products, Services and Solutions
5.10.4 Pfizer, Inc Pharmacogenomics (PGx) Revenue (US$ Million) & (2018-2023)
5.10.5 Pfizer, Inc Recent Developments
5.11 Qiagen, Inc.
5.11.1 Qiagen, Inc. Profile
5.11.2 Qiagen, Inc. Main Business
5.11.3 Qiagen, Inc. Pharmacogenomics (PGx) Products, Services and Solutions
5.11.4 Qiagen, Inc. Pharmacogenomics (PGx) Revenue (US$ Million) & (2018-2023)
5.11.5 Qiagen, Inc. Recent Developments
5.12 Rocheg
5.12.1 Rocheg Profile
5.12.2 Rocheg Main Business
5.12.3 Rocheg Pharmacogenomics (PGx) Products, Services and Solutions
5.12.4 Rocheg Pharmacogenomics (PGx) Revenue (US$ Million) & (2018-2023)
5.12.5 Rocheg Recent Developments
5.13 Teva Pharmaceutical Industries Ltd.
5.13.1 Teva Pharmaceutical Industries Ltd. Profile
5.13.2 Teva Pharmaceutical Industries Ltd. Main Business
5.13.3 Teva Pharmaceutical Industries Ltd. Pharmacogenomics (PGx) Products, Services and Solutions
5.13.4 Teva Pharmaceutical Industries Ltd. Pharmacogenomics (PGx) Revenue (US$ Million) & (2018-2023)
5.13.5 Teva Pharmaceutical Industries Ltd. Recent Developments
5.14 Thermo Fisher Scientific
5.14.1 Thermo Fisher Scientific Profile
5.14.2 Thermo Fisher Scientific Main Business
5.14.3 Thermo Fisher Scientific Pharmacogenomics (PGx) Products, Services and Solutions
5.14.4 Thermo Fisher Scientific Pharmacogenomics (PGx) Revenue (US$ Million) & (2018-2023)
5.14.5 Thermo Fisher Scientific Recent Developments
5.15 Transgenomic, Inc.
5.15.1 Transgenomic, Inc. Profile
5.15.2 Transgenomic, Inc. Main Business
5.15.3 Transgenomic, Inc. Pharmacogenomics (PGx) Products, Services and Solutions
5.15.4 Transgenomic, Inc. Pharmacogenomics (PGx) Revenue (US$ Million) & (2018-2023)
5.15.5 Transgenomic, Inc. Recent Developments
6 North America
6.1 North America Pharmacogenomics (PGx) Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Pharmacogenomics (PGx) Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Pharmacogenomics (PGx) Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Pharmacogenomics (PGx) Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Pharmacogenomics (PGx) Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Pharmacogenomics (PGx) Market Dynamics
11.1 Pharmacogenomics (PGx) Industry Trends
11.2 Pharmacogenomics (PGx) Market Drivers
11.3 Pharmacogenomics (PGx) Market Challenges
11.4 Pharmacogenomics (PGx) Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Industrial Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
